- Announcements
- 2 min read
Monash Health is proud to announce that it is the first health service in Victoria to start a patient on VYALEV, a new 24-hour infusion treatment for people with advanced Parkinson’s disease.
This marks a major step forward in the management of Parkinson’s, offering a simpler and more consistent way to deliver medication to those whose symptoms are no longer well controlled with tablet medications.
Parkinson’s disease is a brain disorder that causes unintended or uncontrollable movements, such as shaking, stiffness, and difficulty with balance and coordination. Symptoms usually begin gradually and worsen over time.
VYALEV works by continuously delivering medication under the skin. This helps keep Parkinson’s symptoms more stable throughout the day by reducing “off” periods – times when symptoms return – and improving overall mobility and quality of life.
The medication is delivered through a small, discreet pump worn on the body.
‘This is a game-changer for patients who struggle with unpredictable symptoms despite multiple medications,’ said Dr Nirosen Vijiaratnam, neurologist and Director of the Movement Disorder Program at Monash Health.
‘VYALEV gives us a way to deliver treatment continuously – without the need for surgery – helping people regain more control over their day-to-day lives.’
Dr Nirosen Vijiaratnam
Now Subsidised Under the PBS from 1 August 2025
VYALEV was listed on the Pharmaceutical Benefits Scheme (PBS) on 1 August 2025, significantly reducing the cost for eligible Australian patients. This ensures broader access to the therapy and supports patients and families managing the challenges of advanced Parkinson’s disease.
Global Recognition: Parkinson’s Foundation Center of Excellence
Monash Health’s Movement Disorders Program offers leading care for over 1,500 patients with Parkinson’s disease.
We are Australia’s only site recognised as a Parkinson’s Foundation Center of Excellence by the American Parkinson’s Disease Foundation – a designation held by a select group of expert centres worldwide.
This designation reflects our leadership in comprehensive Parkinson’s care, including advanced therapies, multidisciplinary support, and cutting-edge research.
First Patient Starts Treatment at Monash Health
The first Australian patient was recently initiated on VYALEV at Monash Health, supported by a team of neurologists, nurses, and pharmacists. The patient was trained to use the discreet, wearable pump at home, with ongoing clinical support.
This treatment may not be appropriate for all patients, and some individuals could experience side effects.
